BioInformant

Your Global Leader in Stem Cell Market Research

Home » MSC

Could Cynata’s Cymerus™ Platform Be A Tool in the War Against Coronavirus?

By

What is the Cymerus™ technology and how could it potentially assist in the battle against Coronavirus cases on a global basis? Cymerus™ is a stem cell manufacturing platform being developed by Cynata Therapeutics Limited (ASX: CYP), an Australian regenerative medicine company.

The proprietary technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating mesenchymoangioblasts (MCAs). It then differentiates these cells into mesenchymal stem cells (MSCs). [Read more…]

Longeveron LLC Announces Completion of Enrollment in Phase 1 Clinical Trial of Longeveron Allogeneic Mesenchymal Stem Cells (LMSCs) in Alzheimer’s Disease

By

MIAMI, Dec. 20, 2019 — Longeveron LLC, a leading developer of adult stem cell technologies for chronic, aging-related and life-threatening conditions, announced today that it has completed enrollment in its Phase 1 Alzheimer’s disease trial. This randomized, double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of LMSCs in patients with mild Alzheimer’s disease (AD). [Read more…]

denovoMATRIX Introduces Ready-to-use, Chemically Defined Coated Cell Cultureware for Serum-free hMSC Expansion

By

August 22, 2019, Dresden, Germany — Due to their high accessibility and extensive beneficial properties, human Mesenchymal Stem Cells (hMSC) offer exciting promises in a plethora of applications in regenerative medicine, particularly in cell-based therapies. The major challenge of hMSC-based therapy is the large-scale expansion of cells in order to achieve the cell numbers necessary for therapeutic treatment. [Read more…]

Introducing the Dawn of MSCs with RoosterBio Founder, Jon Rowley

By

RoosterBioFounded by Dr. Jon Rowley, RoosterBio is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable regenerative medicine industry. Its products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. I had the honor of interviewing Dr. Jon Rowley, who is now the CTO of RoosterBio.

In this interview, we explore RoosterBio’s recent product launches, collaborations, achievements and future trajectory.    [Read more…]

BioInformant's World-Class Clients